Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × pegfilgrastim × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 1

Interventions

pembrolizumab 42 Carboplatin 37 Cisplatin 32 Paclitaxel 26 Nivolumab 22 Pemetrexed 22 Gemcitabine 21 Dexamethasone 19 Rituximab 17 Ipilimumab 16 Cyclophosphamide 15 Fluorouracil 12 Lenalidomide 12 Capecitabine 11 Docetaxel 11 atezolizumab 11 Bevacizumab 10 Cytarabine 10 Prednisone 10 daratumumab 10 durvalumab 10 trastuzumab deruxtecan 10 Bortezomib 9 olaparib 9 130-nm albumin-bound paclitaxel 8 Doxorubicin 8 Leucovorin 8 Trastuzumab 8 Bendamustine Hydrochloride 7 Crizotinib 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03036488 2025-10-29

MK-3475-522

Merck Sharp & Dohme LLC

Phase 3 Completed

1,174 enrolled 1 FDA

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡